Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis
- PMID: 28961801
- DOI: 10.1093/jac/dkx315
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis
Abstract
Objectives: To evaluate the influence on mortality of empirical double-active combination antimicrobial therapy (DACT) compared with active monotherapy (AM) in septic shock patients.
Methods: A retrospective study was performed of monomicrobial septic shock patients admitted to a university centre during 2010-15. A propensity score (PS) was calculated using a logistic regression model taking the assigned therapy as the dependent variable, and used as a covariate in multivariate analysis predicting 7, 15 and 30 day mortality and for matching patients who received DACT or AM. Multivariate models comprising the assigned therapy group and the PS were built for specific patient subgroups.
Results: Five-hundred and seventy-six patients with monomicrobial septic shock who received active empirical antimicrobial therapy were included. Of these, 340 received AM and 236 DACT. No difference in 7, 15 and 30 day all-cause mortality was found between groups either in the PS-adjusted multivariate logistic regression analysis or in the PS-matched cohorts. However, in patients with neutropenia, DACT was independently associated with a better outcome at 15 (OR 0.29, 95% CI 0.09-0.92) and 30 (OR 0.25, 95% CI 0.08-0.79) days, while in patients with Pseudomonas aeruginosa infection DACT was associated with lower 7 (OR 0.12, 95% CI 0.02-0.7) and 30 day (OR 0.26, 95% CI 0.08-0.92) mortality.
Conclusions: All-cause mortality at 7, 15 and 30 days was similar in patients with monomicrobial septic shock receiving empirical double-active combination therapy and active monotherapy. However, a beneficial influence of empirical double-active combination on mortality in patients with neutropenia and those with P. aeruginosa infection is worthy of further study.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Comment in
-
Comment on: Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.J Antimicrob Chemother. 2018 Jun 1;73(6):1731-1735. doi: 10.1093/jac/dky035. J Antimicrob Chemother. 2018. PMID: 29462308 No abstract available.
Similar articles
-
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis-authors' response.J Antimicrob Chemother. 2018 Jun 1;73(6):1732-1733. doi: 10.1093/jac/dky063. J Antimicrob Chemother. 2018. PMID: 29506238 No abstract available.
-
Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.J Antimicrob Chemother. 2024 Nov 4;79(11):2846-2853. doi: 10.1093/jac/dkae296. J Antimicrob Chemother. 2024. PMID: 39224938
-
Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis.Hepatology. 2012 Dec;56(6):2305-15. doi: 10.1002/hep.25931. Hepatology. 2012. PMID: 22753144 Free PMC article.
-
Propensity-based study of aminoglycoside nephrotoxicity in patients with severe sepsis or septic shock.Antimicrob Agents Chemother. 2014 Dec;58(12):7468-74. doi: 10.1128/AAC.03750-14. Epub 2014 Oct 6. Antimicrob Agents Chemother. 2014. PMID: 25288085 Free PMC article.
-
Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis.Crit Care Med. 2010 Sep;38(9):1773-85. doi: 10.1097/CCM.0b013e3181eb3ccd. Crit Care Med. 2010. PMID: 20639750 Review.
Cited by
-
Single-drug versus combination antimicrobial therapy in critically ill patients with hospital-acquired pneumonia and ventilator-associated pneumonia due to Gram-negative pathogens: a multicenter retrospective cohort study.Crit Care. 2024 Jan 3;28(1):10. doi: 10.1186/s13054-023-04792-0. Crit Care. 2024. PMID: 38172969 Free PMC article.
-
Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program.Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):102-107. doi: 10.37201/req/s03.22.2022. Epub 2022 Oct 24. Rev Esp Quimioter. 2022. PMID: 36285869 Free PMC article. Review.
-
Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.Microbiol Spectr. 2022 Jun 29;10(3):e0052522. doi: 10.1128/spectrum.00525-22. Epub 2022 Apr 20. Microbiol Spectr. 2022. PMID: 35442072 Free PMC article.
-
Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.Antimicrob Agents Chemother. 2022 May 17;66(5):e0214021. doi: 10.1128/aac.02140-21. Epub 2022 Apr 7. Antimicrob Agents Chemother. 2022. PMID: 35389238 Free PMC article.
-
Timing of antibiotic therapy in the ICU.Crit Care. 2021 Oct 15;25(1):360. doi: 10.1186/s13054-021-03787-z. Crit Care. 2021. PMID: 34654462 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
